作者
Kris G Samsom, Linda JW Bosch, Luuk J Schipper, Paul Roepman, Ewart de Bruijn, Louisa R Hoes, Immy Riethorst, Lieke Schoenmaker, Lizet E van der Kolk, Valesca P Retèl, Geert WJ Frederix, Tineke E Buffart, Jacobus JM van der Hoeven, Emile E Voest, Edwin Cuppen, Kim Monkhorst, Gerrit A Meijer
发表日期
2020/12
期刊
BMC medical genomics
卷号
13
页码范围
1-7
出版商
BioMed Central
简介
Background
‘Precision oncology’ can ensure the best suitable treatment at the right time by tailoring treatment towards individual patient and comprehensive tumour characteristics. In current molecular pathology, diagnostic tests which are part of the standard of care (SOC) only cover a limited part of the spectrum of genomic changes, and often are performed in an iterative way. This occurs at the expense of valuable patient time, available tissue sample, and interferes with ‘first time right’ treatment decisions. Whole Genome Sequencing (WGS) captures a near complete view of genomic characteristics of a tumour in a single test. Moreover, WGS facilitates faster implementation of new treatment relevant biomarkers. At present, WGS mainly has been applied in study settings, but its performance in a routine diagnostic setting remains to be evaluated. The WIDE study aims to investigate the feasibility and validity of …
引用总数